PE20050017A1 - PHARMACEUTICAL FORMULATION INCLUDING 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL-SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOLE [4,3-d] PYRIMIDIN-7- ONA CITRATE AND PROCESS FOR ITS MANUFACTURE - Google Patents

PHARMACEUTICAL FORMULATION INCLUDING 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL-SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOLE [4,3-d] PYRIMIDIN-7- ONA CITRATE AND PROCESS FOR ITS MANUFACTURE

Info

Publication number
PE20050017A1
PE20050017A1 PE2004000358A PE2004000358A PE20050017A1 PE 20050017 A1 PE20050017 A1 PE 20050017A1 PE 2004000358 A PE2004000358 A PE 2004000358A PE 2004000358 A PE2004000358 A PE 2004000358A PE 20050017 A1 PE20050017 A1 PE 20050017A1
Authority
PE
Peru
Prior art keywords
sulfonil
etoxy
ona
methylpiperazin
pyrimidin
Prior art date
Application number
PE2004000358A
Other languages
Spanish (es)
Inventor
Betancourt Carlos Luis Capre
Original Assignee
Betancourt Carlos Luis Capre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betancourt Carlos Luis Capre filed Critical Betancourt Carlos Luis Capre
Publication of PE20050017A1 publication Critical patent/PE20050017A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA MASTICABLE PARA ADMINISTRACION ORAL QUE COMPRENDE: (a) 5-[2-ETOXI-5(4-METILPIPERAZIN-1-IL SULFONIL)FENIL]-1,6-DIHIDRO-1-METIL-3-PROPIL PIRAZOLO [4,3-d] PIRIMIDIN-7-ONA CITRATO (SILDENAFIL) DE FORMULA I EN CONCENTRACIONES DE 1% A 40% SOBRE EL PESO TOTAL DE LA FORMULACION, Y (b) EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES EN UN PORCENTAJE ENTRE 90% Y 95% DEL PESO TOTAL DE LA FORMULACION. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE DICHA FORMULACION QUE SE CARACTERIZA PORQUE LAS TABLETAS PRESENTAN MICROPOROS QUE PERMITEN UNA RAPIDA DESINTEGRACION POR EFECTO DE LA PENETRACION DE LA SALIVA Y SU ACCION SOBRE EL PRINCIPIO ACTIVOREFERS TO A CHEWABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION, INCLUDING: (a) 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYL PIRAZOLO [4,3-d] PYRIMIDIN-7-ONA CITRATE (SILDENAFIL) OF FORMULA I IN CONCENTRATIONS OF 1% TO 40% ON THE TOTAL WEIGHT OF THE FORMULATION, AND (b) PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS IN A PERCENTAGE BETWEEN 90% AND 95% OF THE TOTAL WEIGHT OF THE FORMULATION. IT ALSO REFERS TO A PROCEDURE FOR THE PREPARATION OF SUCH FORMULATION WHICH IS CHARACTERIZED BECAUSE THE TABLETS PRESENT MICROPORES THAT ALLOW A RAPID DISINTEGRATION BY THE EFFECT OF THE PENETRATION OF SALIVA AND ITS ACTION ON THE ACTIVE PRINCIPLE

PE2004000358A 2003-04-09 2004-04-07 PHARMACEUTICAL FORMULATION INCLUDING 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL-SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOLE [4,3-d] PYRIMIDIN-7- ONA CITRATE AND PROCESS FOR ITS MANUFACTURE PE20050017A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CO03029961A CO5330617A1 (en) 2003-04-09 2003-04-09 NEW ORAL SOLID DOSAGE FORM OF 5- [2-ETOXI-5 (4-METHYLPIPERAZIN-1-IL SULFONYL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOL [4,3-D] PIRIMIDIN- 7-ONA CITRATE AND PROCESS FOR MANUFACTURING

Publications (1)

Publication Number Publication Date
PE20050017A1 true PE20050017A1 (en) 2005-02-24

Family

ID=40435089

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000358A PE20050017A1 (en) 2003-04-09 2004-04-07 PHARMACEUTICAL FORMULATION INCLUDING 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL-SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOLE [4,3-d] PYRIMIDIN-7- ONA CITRATE AND PROCESS FOR ITS MANUFACTURE

Country Status (4)

Country Link
CO (1) CO5330617A1 (en)
EC (1) ECSP045048A (en)
GT (1) GT200400059A (en)
PE (1) PE20050017A1 (en)

Also Published As

Publication number Publication date
ECSP045048A (en) 2004-05-28
GT200400059A (en) 2005-02-01
CO5330617A1 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
AR048431A1 (en) GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
AR108594A2 (en) PHARMACEUTICAL FORMULATIONS THAT KEEP FLAVOR WITH IMPROVED PHARMACEUTICAL CHARACTERISTICS
AR019935A1 (en) SOLID PREPARATION OF QUICK DISINTEGRATION, USE OF A LITTLE CELLULOSE HYDROXIPROPIL REPLACED IN SUCH PREPARATION AND METHOD TO IMPROVE THE CAPACITY OF FAST DETACHMENT OF THE SAME
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
BR122019027412B8 (en) sustained release pharmaceutical composition in the form of microparticles, process for preparing said microparticles, and administration kit
MX2009003030A (en) Galenic form for the trans-mucosal delivery of active ingredients.
CO6270217A2 (en) GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN
ECSP034826A (en) METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION OF LOW DOSE
AR061166A1 (en) PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF PHENYLPHERINE
AR062659A1 (en) COMPOSITION OF LEVODOPA SUSTAINED RELEASE AND METHOD FOR USE
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
ES2175663T3 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS.
AR061233A1 (en) FORMULATION OF PROLONGED LIBERATION OF NALTREXONA
UY30847A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
CO5580741A2 (en) PHARMACEUTICAL COMPOSITION INCLUDING A 5HT1 RECEIVER AGONIST
AR065582A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
AR048970A1 (en) SOLID PHARMACEUTICAL FORMULATION
MA32722B1 (en) GALENIC FORMULATION COMPRISING ALISKIRENE AND ASSOCIATED PREPARATION METHOD BY FUSION-EXTRUSION GRANULATION
PE20050017A1 (en) PHARMACEUTICAL FORMULATION INCLUDING 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL-SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOLE [4,3-d] PYRIMIDIN-7- ONA CITRATE AND PROCESS FOR ITS MANUFACTURE
ES2678122T3 (en) Mucoadherent buccal tablets for the treatment of orofacial herpes
KR20200131913A (en) Pharmaceutical compositions comprising flurbiprofen
BRPI0907203A2 (en) Dosage form for oral transmucosal administration of triptans
PE20110923A1 (en) PRE-COMPACTED RAPID DISINTEGRATION FORMULATIONS OF COMPOUNDS WITH LOW ORAL BIODAVAILABILITY
AR030551A1 (en) USE OF NEFIRACETAM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE PROCESSING OF THE RESULTING PHARMACEUTICAL NEURODEGENERATION AND COMPOSITION
JP2009507850A5 (en)

Legal Events

Date Code Title Description
FC Refusal